New · GLP-1 pills · From $149/mo→Learn more
clyne™
Concierge
TREATMENTS → WEIGHT LOSS● PHYSICIAN-MANAGED PROGRAM12-WEEK PROGRAM
01 — TWELVE WEEKS

Up to 15% weight loss.
Your first 12 weeks start here.

The Clyne program pairs a GLP-1 prescribed by a US physician with Clyne Concierge for daily questions and a care team that watches your dose, your symptoms, and your week — and moves before you plateau.

$149
/MO · ORAL GLP-1
Includes Clyne Concierge + physician care + pharmacy ship
02 — YOUR CALENDAR

What actually
happens, week by week.

ILLUSTRATIVE 12-WEEK TRAJECTORY · BASED ON PUBLISHED TRIAL DATA
WK 01WK 02WK 03WK 04WK 05WK 06WK 07WK 08WK 09WK 10WK 11WK 12
220 lb212 lb200 lb192 lb187 lb
WEEKS 1–3
Titrate gently
Start at 3 mg. Nausea peaks. Log dose and symptoms in Clyne Concierge; your care team watches the data.
WEEKS 4–6
Cravings quiet
You notice fullness earlier. First 4–6 lb typically gone.
WEEKS 7–9
Compound
Physician reviews labs. Dose escalates if symptoms allow.
WEEKS 10–12
Lock it in
Protein + lift plan kicks in to protect lean mass.
03 — WHAT'S INCLUDED
THE MEDICATION
Foundayo™
oral GLP-1
  • ✦ No needles, no cold chain
  • ✦ Same molecule class as Wegovy
  • ✦ Refills auto-ship at day 25
Stay on track
Anytime
Log your dose, symptoms, and appetite. Clyne Concierge explains what's happening; your care team monitors progress.
Physician care
Same biz day
Your US-licensed doctor is two taps away.
Body comp
3 scans
At-home DXA-alt kit at week 0, 6, 12.
THE HARD NO

When we turn you away.

×BMI < 27 with no comorbidities
×Active pregnancy or trying
×History of medullary thyroid carcinoma
×Active pancreatitis or severe GERD
●FDA-approved molecules●Daily oral · no needles●Compounded injectable optional●Physician-managed dose titration●Resistance-training guidance●Cancel any time●HSA / FSA accepted●FDA-approved molecules●Daily oral · no needles●Compounded injectable optional●Physician-managed dose titration●Resistance-training guidance●Cancel any time●HSA / FSA accepted●FDA-approved molecules●Daily oral · no needles●Compounded injectable optional●Physician-managed dose titration●Resistance-training guidance●Cancel any time●HSA / FSA accepted
MEMBER · ANONYMIZED
Member, 0
ILLUSTRATIVE · 12-week program
OUTCOME
Trial-data baseline: STEP 1 (NEJM 2021) mean weight loss 14.9% at 68 weeks on semaglutide 2.4 mg; SURMOUNT-1 (NEJM 2022) 15.0–20.9% across tirzepatide doses at 72 weeks. Individual results vary.
DAY 0

Free 4-minute intake.

A typical 12-week program starts here. You complete a structured intake about medical history, current medications, and weight history. Your physician reviews your case (typically same business day) and either approves a starting dose, asks for a clarifying message, or refers you to a different pathway.

Intake complete
WEEK 1

Starting dose. Days 1–4 set the baseline.

Foundayo or compounded oral semaglutide titration begins at the low starting dose. Most members tolerate the first week without significant nausea. Clyne Concierge can answer questions about what to expect; your care team logs symptoms and adjusts only if needed.

Lowest dose
WEEK 4

Appetite signal changes.

STEP 1 (NEJM 2021) reported mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg, with the largest acceleration starting in the first weeks. By week 4 the trial cohort had begun the steady reduction phase. Dose adjustments — up or down — are physician-driven, not algorithmic.

Steady reduction phase begins
WEEK 6

Lean-mass conversation.

Per the lean-mass meta-analysis (Obesity 2023), 25–39% of total GLP-1 weight loss is lean mass without intervention. Resistance training plus 1.4 g/kg protein attenuates that by ~50% per the same review. Your care team discusses protein targets and any movement plan you'd like to add.

Resistance + protein plan
WEEK 9

Plateau is expected.

Weight loss on GLP-1s is rarely linear. Plateaus of 1–2 weeks at any stage are normal. Your physician reviews labs (TSH, CMP) and either holds the dose or adjusts based on tolerability and trend.

WEEK 12

First program block ends.

SURMOUNT-1 (NEJM 2022) reported 15.0% / 19.5% / 20.9% mean weight loss across tirzepatide doses at 72 weeks. STEP 1 reported 14.9% on semaglutide 2.4 mg at 68 weeks. Where any individual member lands is reviewed with their physician; a maintenance plan or dose adjustment is set at this point.

Maintenance plan set
MAINTENANCE

Off-ramp planned from day 1.

Per STEP 4 (JAMA 2021), members who discontinued semaglutide regained ~2/3 of lost weight within 12 months. Continued therapy maintained loss. Obesity is a chronic condition; your physician designs a maintenance dose with that in mind.

Maintenance dose · long-term
04 — WHAT IT COSTS

Three molecules. One subscription.

One subscription. Cancel any time. Labs, follow-ups, and Clyne Concierge included.

ORAL GLP-1
$149/ month
MOST POPULAR
Foundayo™ daily oral orforglipron. No needles, no cold chain.
  • Daily oral orforglipron 3 → 14 mg titration
  • Clyne Concierge: log dose and symptoms anytime
  • Physician review monthly
  • Care-team messaging unlimited
Start oral
INJECTABLE
$299/ month
Includes shipping
Compounded semaglutide weekly injection.
  • Weekly injection 0.25 → 2.4 mg titration
  • US-licensed compounding pharmacy
  • Cold-chain shipping included
  • Same Concierge + physician care
Start injectable
TIRZEPATIDE
$349/ month
Requires intake review
Compounded tirzepatide for non-responders or higher targets.
  • Weekly injection 2.5 → 15 mg titration
  • Better lean preservation in trials
  • Endo + obesity medicine review
  • Care-team messaging unlimited
Talk to a doctor
06 — WHO PRESCRIBES

Real doctors. Not a chatbot in a lab coat.

Every prescription is signed by a US-licensed physician on staff. They review the AI summary, the intake, and the bloodwork — then make the call.

Your physician
US-licensed, board-certified

Your physician is US-licensed, board-certified, and reviews every case personally.

50 STATE LIC.
06 — EVIDENCE

The trial data. Cited.

01
STEP 1: semaglutide 2.4 mg in adults with overweight
Mean weight loss 14.9% at 68 weeks vs. 2.4% placebo. 50.5% lost ≥15% body weight.
02
PIONEER 4: oral semaglutide vs. liraglutide vs. placebo
Oral semaglutide non-inferior to injectable liraglutide on A1c, superior on weight loss.
03
SURMOUNT-1: tirzepatide 5/10/15 mg
Weight loss 15.0% / 19.5% / 20.9% at 72 weeks. First single-agent therapy approaching bariatric outcomes.
04
Lean mass loss on GLP-1 receptor agonists: meta-analysis
Lean mass accounts for 25–39% of total weight lost. Resistance training + 1.4 g/kg protein attenuates by ~50%.
05
Maintenance after GLP-1 discontinuation (STEP 4)
Members who discontinued regained 2/3 of lost weight within 1 year. Continued therapy maintained loss.
06
Cardiovascular outcomes (SELECT)
Semaglutide 2.4 mg reduced major adverse cardiovascular events 20% in non-diabetic adults with obesity.
07 — FREQUENTLY ASKED

The questions every member asks. Answered straight.

About 25–39% of total weight loss on a GLP-1 is lean mass — that's the literature. With a protein-and-resistance plan (110+ g protein, two strength sessions/week), most members keep that closer to 15–20%. We won't pretend muscle loss isn't a thing; we just have a plan for it.

Per the STEP 4 trial, members who discontinued regained about 2/3 of lost weight within a year. The honest framing is that obesity is a chronic condition. Most members stay on a maintenance dose long-term. We design every plan with the off-ramp in mind so you understand the tradeoff.

Foundayo™ is orforglipron — a different molecule from Eli Lilly, not semaglutide. Our injectable plan is compounded semaglutide (same molecule as Ozempic and Wegovy). We don't sell brand-name Ozempic at retail; the compounded routes are how the price works.

Free 4-minute intake. Physician review typically same business day. Pharmacy ships after approval. Most US addresses get the first month within 3–5 business days.

GLP-1s are notoriously hard to get covered for weight loss. We don't bill insurance — the cash price IS the price. HSA/FSA cards work. We'll send a superbill on request for your own reimbursement attempts.

Real: nausea (44%), constipation (24%), diarrhea (30%), fatigue early on. Manageable with slow titration and dietary adjustments. Rare: pancreatitis (<0.1%) — severe abdominal pain means stop and go to ER. Hype: gastroparesis. Slowed gastric emptying is the mechanism, not a complication.

Pharmacologically yes, but most members find their tolerance drops dramatically — sometimes to two drinks max. Many people find their relationship with alcohol shifts on GLP-1s, often in ways they're glad about.

Probably not. The FDA indication is BMI ≥30, or ≥27 with at least one comorbidity (hypertension, prediabetes, sleep apnea, dyslipidemia). We follow the indication. About 14% of intakes get redirected at this gate — we'd rather refer than write the wrong script.

All three are common combinations and generally fine. Metformin pairs well with GLP-1s (often the doses can come down together). SSRIs are no contraindication. Thyroid: we monitor TSH because GLP-1s can change levothyroxine absorption.

Yes. Pause from your dashboard with one click. When you restart, you re-titrate from a lower dose to avoid the GI side effects. Your physician approves the re-start so we can review what's changed in the meantime.

AVAILABLE NOW

Available treatments in this category. Pick a path.

Start your free intakeAsk Clyne Concierge
08 — START THE PROGRAM

Twelve weeks changes the trajectory.

Free 4-minute intake. Physician review typically same business day. Pharmacy ships after approval. Clyne Concierge and your care team are with you from day 1.

ASK CLYNE CONCIERGE

Still deciding? Ask the AI.

No signup. No gated form. Get a physician-reviewed answer in under a minute.